<DOC>
	<DOCNO>NCT01893281</DOCNO>
	<brief_summary>This study evaluate testosterone solution raise testosterone hormone level normal range treatment 9 Weeks , participant document history subtherapeutic level [ total testosterone &lt; 300 nanogram per deciliter ( ng/dL ) ] previously treat topical testosterone gel .</brief_summary>
	<brief_title>The Effect Testosterone Topical Solution ( LY900011 ) Hypogonadal Men With Suboptimal Response Topical Testosterone Gel</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Able read , understand , provide sign informed consent start trial activity relate study ( include discontinue testosterone replacement therapy prior Screening ) Male participant diagnosis hypogonadism document biochemical failure ( total testosterone &lt; 300 ng/dL ) treat high dose topical testosterone gel tolerate participant . Documentation biochemical failure include : name dose topical testosterone gel , lab report show total testosterone level &lt; 300 ng/dL therapy , write chart report state clear lack efficacy , include participant 's serum total testosterone level time failure Screening serum total testosterone level &lt; 300 ng/dL ( base average 2 morning blood sample take least 30 minute apart ) Screening Prostate Specific Antigen ( PSA ) &lt; 4 nanogram per milliliter ( ng/mL ) Screening If participant receive testosterone replacement therapy willing discontinue testosterone replacement therapy enter study , screen total testosterone level check least 14 day discontinue topical therapy , least 28 day participant use shortacting intramuscular ( IM ) therapies Any previous treatment testosterone topical solution ( LY900011 ) Known suspect carcinoma ( history carcinoma ) prostate suspicious nodule digital rectal exam Screening Known suspect breast cancer history breast cancer Severe sleep apnea ( untreated unsuccessfully treat ) opinion study investigator Use longacting IM testosterone undecanoate 6month period prior Screening History use implant testosterone pellet ( Testopel ) International Prostate Symptom Score ( IPSS ) total score &gt; 19 Screening Hematocrit ≥50 % Screening . For site locate elevation ≥4500 foot , participant exclude hematocrit &gt; 54 % accord investigator discretion . Any participant hematocrit &gt; 54 % later study visit withdrawn study Significant history allergy and/or sensitivity drug product excipients , include history sensitivity testosterone and/or sunscreens Dermatologic condition underarm area might interfere testosterone absorption ( example , eczema ) could exacerbate topical testosterone replacement therapy History luteinizing hormonereleasing hormone ( LHRH ) antagonist agonist treatment 6 month prior Screening Exhibit evidence congestive heart failure [ New York Heart Association ( NYHA ) Class 2 ] within 6 month prior Screening Exhibit evidence severe renal impairment [ creatinine clearance &lt; 30 milliliter per minute ( mL/min ) determine CockcroftGault formula ] Screening Exhibit history severe liver disease clinical evidence hepatic impairment Screening Any condition would interfere participant 's ability provide inform consent , comply study instruction , would place participant increase risk , might confound interpretation study result Are investigator site personnel directly affiliate study and/or immediate family . Immediate family define spouse , parent , child , sibling , whether biological legally adopt Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>